Eupraxia Pharmaceuticals Inc.
EPRX Nasdaq Pharmaceutical Preparations Financials FY2022–FY2025
What Eupraxia Pharmaceuticals Inc. does
No business description yet.
- Legal name
- EUPRAXIA PHARMACEUTICALS INC.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 40-F · Mar 13, 2026
- Accession · CIK
- 0001193125-26-104765
0001581178
Revenue and margins
Eupraxia Pharmaceuticals Inc. had $0.0M of revenue in fiscal 2025.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Eupraxia Pharmaceuticals Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 17.8%.
Balance sheet
Cash, debt and the ratios that show how comfortably Eupraxia Pharmaceuticals Inc. can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $18.3M | $19.3M | $33.1M | $80.6M |
| Current ratio | 6.1x | 1.0x | 11.1x | 15.1x |
| Quick ratio | 6.1x | 1.0x | 11.1x | 15.1x |
| Total assets | $19.1M | $20.3M | $34.9M | $86.2M |
| Total liabilities | $11.9M | $19.4M | $3.1M | $5.7M |
| Shareholders' equity | $7.8M | $2.2M | $33.4M | $82.0M |
| Net debt (− = net cash) | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✕ | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✕ | ✓ |
| Debt fell relative to assets | — | — | — | — |
| Current ratio rose | — | ✕ | ✓ | ✓ |
| Share count didn't rise | — | ✕ | ✕ | ✕ |
| Gross margin rose | — | — | — | — |
| Revenue rose relative to assets | — | — | ✕ | ✕ |
| F-score | — / 3 | — / 6 | 2 / 7 | 3 / 7 |
| Accruals ratio | −21.4% | −37.9% | 16.3% | −16.6% |
| Altman Z'' | — | — | — | — |
4 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | $0.0M | $0.0M | $0.0M |
| Research and development | $13.6M | $20.4M | $16.1M | $21.3M |
| Interest expense | $1.0M | $1.2M | $0.6M | $0.0M |
| Pretax income | −$19.0M | −$28.9M | −$25.7M | −$38.6M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | −$18.5M | −$28.2M | −$25.5M | −$38.6M |
| Diluted EPS | −$0.96 | −$1.17 | −$0.76 | −$1.03 |
| Diluted shares | 0.02B | 0.02B | 0.03B | 0.04B |
| Cash flow | ||||
| Cash from operations | −$14.4M | −$20.7M | −$30.0M | −$28.6M |
| Depreciation and amortization | $0.1M | $0.2M | $0.2M | $0.2M |
| Stock-based compensation | $1.4M | $1.4M | $3.2M | $8.8M |
| Balance sheet | ||||
| Cash and short-term investments | $18.3M | $19.3M | $33.1M | $80.6M |
| Current assets | $18.6M | $19.8M | $34.4M | $85.1M |
| Current liabilities | $3.1M | $19.4M | $3.1M | $5.6M |
| Property and equipment, net | $0.4M | $0.4M | $0.4M | $0.8M |
| Total assets | $19.1M | $20.3M | $34.9M | $86.2M |
| Total liabilities | $11.9M | $19.4M | $3.1M | $5.7M |
| Shareholders' equity | $7.8M | $2.2M | $33.4M | $82.0M |
| Returns | ||||
| Return on equity | −237.5% | −564.3% | −143.2% | −66.8% |
| Return on assets | −96.7% | −143.3% | −92.4% | −63.7% |
| Return on tangible equity | −237.5% | −1,273.4% | −76.3% | −47.0% |
| Growth | ||||
| Share count change | — | 25.2% | 40.5% | 17.8% |
| Financial health | ||||
| Current ratio | 6.1x | 1.0x | 11.1x | 15.1x |
| Quick ratio | 6.1x | 1.0x | 11.1x | 15.1x |
| Quality scores | ||||
| Piotroski F-score | — | — | 2.0 | 3.0 |
| Accruals ratio | −21.4% | −37.9% | 16.3% | −16.6% |
Source: SEC EDGAR XBRL filings (CIK 0001581178). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.